Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

136 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A clinical review of bleomycin--a new antineoplastic agent.
Blum RH, Carter SK, Agre K. Blum RH, et al. Cancer. 1973 Apr;31(4):903-14. doi: 10.1002/1097-0142(197304)31:4<903::aid-cncr2820310422>3.0.co;2-n. Cancer. 1973. PMID: 4122362 Clinical Trial. No abstract available.
Current status of American studies with bleomycin.
Carter SK, Blum RH. Carter SK, et al. Among authors: blum rh. Prog Biochem Pharmacol. 1976;11:158-71. Prog Biochem Pharmacol. 1976. PMID: 63960 Review. No abstract available.
New chemotherapeutic agents--bleomycin and adriamycin.
Carter SK, Blum RH. Carter SK, et al. Among authors: blum rh. CA Cancer J Clin. 1974 Nov-Dec;24(6):322-31. doi: 10.3322/canjclin.24.6.322. CA Cancer J Clin. 1974. PMID: 4140753 Free article. No abstract available.
Hexamethylmelamine--a new drug with activity in solid tumors.
Blum RH, Livingston RB, Carter SK. Blum RH, et al. Eur J Cancer (1965). 1973 Mar;9(3):195-202. doi: 10.1016/s0014-2964(73)80019-2. Eur J Cancer (1965). 1973. PMID: 4595749 Clinical Trial. No abstract available.
Pulmonary complications of cancer chemotherapy.
Blum R, Carter SK. Blum R, et al. N Engl J Med. 1973 Feb 1;288(5):266. doi: 10.1056/NEJM197302012880516. N Engl J Med. 1973. PMID: 4682224 No abstract available.
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer.
Davis ID, Martin AJ, Stockler MR, Begbie S, Chi KN, Chowdhury S, Coskinas X, Frydenberg M, Hague WE, Horvath LG, Joshua AM, Lawrence NJ, Marx G, McCaffrey J, McDermott R, McJannett M, North SA, Parnis F, Parulekar W, Pook DW, Reaume MN, Sandhu SK, Tan A, Tan TH, Thomson A, Tu E, Vera-Badillo F, Williams SG, Yip S, Zhang AY, Zielinski RR, Sweeney CJ; ENZAMET Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group. Davis ID, et al. N Engl J Med. 2019 Jul 11;381(2):121-131. doi: 10.1056/NEJMoa1903835. Epub 2019 Jun 2. N Engl J Med. 2019. PMID: 31157964 Clinical Trial.
A phase III randomized trial of adding topical nitroglycerin to first-line chemotherapy for advanced nonsmall-cell lung cancer: the Australasian lung cancer trials group NITRO trial.
Davidson A, Veillard AS, Tognela A, Chan MM, Hughes BG, Boyer M, Briscoe K, Begbie S, Abdi E, Crombie C, Long J, Boyce A, Lewis CR, Varma S, Broad A, Muljadi N, Chinchen S, Espinoza D, Coskinas X, Pavlakis N, Millward M, Stockler MR; Australasian Lung cancer Trials Group (ALTG); Australasian Lung cancer Trials Group ALTG. Davidson A, et al. Ann Oncol. 2015 Nov;26(11):2280-6. doi: 10.1093/annonc/mdv373. Epub 2015 Sep 7. Ann Oncol. 2015. PMID: 26347110 Free article. Clinical Trial.
Real-World Outcomes of Ribociclib and Aromatase Inhibitor Use in First Line Hormone Receptor Positive, HER2-Negative Metastatic Breast Cancer.
Wong V, de Boer R, Baron-Hay S, Blum R, Boyle F, Chua S, Clarke K, Cuff K, Green M, Lim E, Mok K, Nott L, Nottage M, Tafreshi A, Tsoi D, Uccellini A, Hong W, Gibbs P, Lok SW. Wong V, et al. Clin Breast Cancer. 2022 Dec;22(8):792-800. doi: 10.1016/j.clbc.2022.08.011. Epub 2022 Aug 30. Clin Breast Cancer. 2022. PMID: 36151018
136 results